Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $769.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 11.03% to $769.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, up 42.44% year-over-year, with the annual reading at $769.3 million for FY2025, 11.03% down from the prior year.
  • Liabilities and Shareholders Equity hit $769.3 million in Q4 2025 for NewAmsterdam Pharma, down from $786.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $864.6 million in Q4 2024 to a low of $347.1 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $631.8 million across 4 years, with a median of $655.8 million in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 36.0% in 2023 and later soared 149.1% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $542.3 million in 2022, then plummeted by 36.0% to $347.1 million in 2023, then surged by 149.1% to $864.6 million in 2024, then decreased by 11.03% to $769.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for NAMS at $769.3 million in Q4 2025, $786.4 million in Q3 2025, and $815.1 million in Q2 2025.